tirzepatide in stock Demonstrates 94% Diabetes Reduction, 22% Weight Loss SURMOUNT-1 Study Mounjaro will remain off shortage

doi: 10.1111/pce.13602 28 HanY.ChaouchS.MhamdiA.QuevalG.ZechmannB.NoctorG

Your health journey is unique

A review of PubMed, EMBASE and Cochrane from inception through October 2024 yielded three studies from Denmark, Switzerland and the United States comprising 410 patients, including 207 who received GLP-1 receptor agonists

If youre here to learn more about these powerful ingredients, Im here to offer you all the knowledge you need

Adverse events (AEs) were also monitored

These include: Nausea (affecting 20-40% of patients initially) Vomiting Diarrhoea Constipation Abdominal discomfort These effects typically arise from delayed gastric emptying and direct effects on the gastrointestinal tract